20. 副腎白質ジストロフィー [臨床試験数:49,薬物数:86(DrugBank:29),標的遺伝子数:18,標的パスウェイ数:112

Searched query = "Adrenoleukodystrophy", "Adrenomyeloneuropathy", "AMN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03864523January 201616/9/2016Effect of Pioglitazone Administered to Patients With AdrenomyeloneuropathyEffect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy: a Phase II, Single-arm, Multicentric Clinical TrialAdrenomyeloneuropathy;X-linked AdrenoleukodystrophyDrug: PioglitazoneOnofre, Aurora Pujol, M.D.Instituto de Salud Carlos III;Fundacion Hesperia;ELA España AssociationCompleted18 Years65 YearsAll18Phase 2Spain
2EUCTR2011-006113-34-ES24/10/201312/09/2013Effect of pioglitazone in patienst with Adrenomyeloneuropathy.Effect of pioglitazone administred to patients with Adrenomyeloneuropathy: A phase II, Singlearm, Monocentric Trial. - Pioglitazone in Adrenomyeloneuropathy X-linked adrenoleukodystrophy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]INN or Proposed INN: PIOGLITAZONEAURORA PUJOL ONOFRENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Spain